Selected research
Industry Research
Therapeutic Nuclear Drug Industry Research Report 2026
Market perspective
The global Therapeutic Nuclear Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Therapeutic Nuclear Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Therapeutic Nuclear Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Therapeutic Nuclear Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Therapeutic Nuclear Drug include Novartis, Dongcheng, Bayer, Q BioMed, Mundipharma, Lantheus, Jubilant Radiopharma, International Isotopes and Curium Pharmaceuticals, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Therapeutic Nuclear Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Therapeutic Nuclear Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Therapeutic Nuclear Drug Market by Company
Novartis
Dongcheng
Bayer
Q BioMed
Mundipharma
Lantheus
Jubilant Radiopharma
International Isotopes
Curium Pharmaceuticals
China Isotope & Radiation
Aurobindo Pharma
Therapeutic Nuclear Drug Segment by Type
Lutetium-177
Radium-223
Iodine-131
Other
Therapeutic Nuclear Drug Segment by Application
Lymphoma
Thyroid
Bone Metastasis
Other
Therapeutic Nuclear Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Nuclear Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Nuclear Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Nuclear Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Therapeutic Nuclear Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Lutetium-177
- Radium-223
- Iodine-131
- Other
Applications
- Lymphoma
- Thyroid
- Bone Metastasis
- Other
Companies covered
- Novartis
- Dongcheng
- Bayer
- Q BioMed
- Mundipharma
- Lantheus
- Jubilant Radiopharma
- International Isotopes
- Curium Pharmaceuticals
- China Isotope & Radiation
- Aurobindo Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Therapeutic Nuclear Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Lutetium-177
- 2.2.3 Radium-223
- 2.2.4 Iodine-131
- 2.2.5 Other
- 2.3 Therapeutic Nuclear Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Lymphoma
- 2.3.3 Thyroid
- 2.3.4 Bone Metastasis
- 2.3.5 Other
- 2.4 Assumptions and Limitations
3 Therapeutic Nuclear Drug Breakdown Data by Type
- 3.1 Global Therapeutic Nuclear Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Therapeutic Nuclear Drug Forecasted Market Size by Type (2027-2032)
4 Therapeutic Nuclear Drug Breakdown Data by Application
- 4.1 Global Therapeutic Nuclear Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Therapeutic Nuclear Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Therapeutic Nuclear Drug Market Perspective (2021-2032)
- 5.2 Global Therapeutic Nuclear Drug Growth Trends by Region
- 5.2.1 Global Therapeutic Nuclear Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Therapeutic Nuclear Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Therapeutic Nuclear Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Therapeutic Nuclear Drug Market Dynamics
- 5.3.1 Therapeutic Nuclear Drug Industry Trends
- 5.3.2 Therapeutic Nuclear Drug Market Drivers
- 5.3.3 Therapeutic Nuclear Drug Market Challenges
- 5.3.4 Therapeutic Nuclear Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Therapeutic Nuclear Drug Players by Revenue
- 6.1.1 Global Top Therapeutic Nuclear Drug Players by Revenue (2021-2026)
- 6.1.2 Global Therapeutic Nuclear Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Therapeutic Nuclear Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Therapeutic Nuclear Drug Head Office and Area Served
- 6.4 Global Therapeutic Nuclear Drug Players, Product Type & Application
- 6.5 Global Therapeutic Nuclear Drug Manufacturers Established Date
- 6.6 Global Therapeutic Nuclear Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Therapeutic Nuclear Drug Market Size (2021-2032)
- 7.2 North America Therapeutic Nuclear Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Therapeutic Nuclear Drug Market Size by Country (2021-2026)
- 7.4 North America Therapeutic Nuclear Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Therapeutic Nuclear Drug Market Size (2021-2032)
- 8.2 Europe Therapeutic Nuclear Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Therapeutic Nuclear Drug Market Size by Country (2021-2026)
- 8.4 Europe Therapeutic Nuclear Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Therapeutic Nuclear Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Therapeutic Nuclear Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Therapeutic Nuclear Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Therapeutic Nuclear Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Therapeutic Nuclear Drug Market Size (2021-2032)
- 10.2 South America Therapeutic Nuclear Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Therapeutic Nuclear Drug Market Size by Country (2021-2026)
- 10.4 South America Therapeutic Nuclear Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Therapeutic Nuclear Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Therapeutic Nuclear Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Therapeutic Nuclear Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Therapeutic Nuclear Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Novartis
- 12.1.1 Novartis Company Information
- 12.1.2 Novartis Business Overview
- 12.1.3 Novartis Revenue in Therapeutic Nuclear Drug Business (2021-2026)
- 12.1.4 Novartis Therapeutic Nuclear Drug Product Portfolio
- 12.1.5 Novartis Recent Developments
- 12.2 Dongcheng
- 12.2.1 Dongcheng Company Information
- 12.2.2 Dongcheng Business Overview
- 12.2.3 Dongcheng Revenue in Therapeutic Nuclear Drug Business (2021-2026)
- 12.2.4 Dongcheng Therapeutic Nuclear Drug Product Portfolio
- 12.2.5 Dongcheng Recent Developments
- 12.3 Bayer
- 12.3.1 Bayer Company Information
- 12.3.2 Bayer Business Overview
- 12.3.3 Bayer Revenue in Therapeutic Nuclear Drug Business (2021-2026)
- 12.3.4 Bayer Therapeutic Nuclear Drug Product Portfolio
- 12.3.5 Bayer Recent Developments
- 12.4 Q BioMed
- 12.4.1 Q BioMed Company Information
- 12.4.2 Q BioMed Business Overview
- 12.4.3 Q BioMed Revenue in Therapeutic Nuclear Drug Business (2021-2026)
- 12.4.4 Q BioMed Therapeutic Nuclear Drug Product Portfolio
- 12.4.5 Q BioMed Recent Developments
- 12.5 Mundipharma
- 12.5.1 Mundipharma Company Information
- 12.5.2 Mundipharma Business Overview
- 12.5.3 Mundipharma Revenue in Therapeutic Nuclear Drug Business (2021-2026)
- 12.5.4 Mundipharma Therapeutic Nuclear Drug Product Portfolio
- 12.5.5 Mundipharma Recent Developments
- 12.6 Lantheus
- 12.6.1 Lantheus Company Information
- 12.6.2 Lantheus Business Overview
- 12.6.3 Lantheus Revenue in Therapeutic Nuclear Drug Business (2021-2026)
- 12.6.4 Lantheus Therapeutic Nuclear Drug Product Portfolio
- 12.6.5 Lantheus Recent Developments
- 12.7 Jubilant Radiopharma
- 12.7.1 Jubilant Radiopharma Company Information
- 12.7.2 Jubilant Radiopharma Business Overview
- 12.7.3 Jubilant Radiopharma Revenue in Therapeutic Nuclear Drug Business (2021-2026)
- 12.7.4 Jubilant Radiopharma Therapeutic Nuclear Drug Product Portfolio
- 12.7.5 Jubilant Radiopharma Recent Developments
- 12.8 International Isotopes
- 12.8.1 International Isotopes Company Information
- 12.8.2 International Isotopes Business Overview
- 12.8.3 International Isotopes Revenue in Therapeutic Nuclear Drug Business (2021-2026)
- 12.8.4 International Isotopes Therapeutic Nuclear Drug Product Portfolio
- 12.8.5 International Isotopes Recent Developments
- 12.9 Curium Pharmaceuticals
- 12.9.1 Curium Pharmaceuticals Company Information
- 12.9.2 Curium Pharmaceuticals Business Overview
- 12.9.3 Curium Pharmaceuticals Revenue in Therapeutic Nuclear Drug Business (2021-2026)
- 12.9.4 Curium Pharmaceuticals Therapeutic Nuclear Drug Product Portfolio
- 12.9.5 Curium Pharmaceuticals Recent Developments
- 12.10 China Isotope & Radiation
- 12.10.1 China Isotope & Radiation Company Information
- 12.10.2 China Isotope & Radiation Business Overview
- 12.10.3 China Isotope & Radiation Revenue in Therapeutic Nuclear Drug Business (2021-2026)
- 12.10.4 China Isotope & Radiation Therapeutic Nuclear Drug Product Portfolio
- 12.10.5 China Isotope & Radiation Recent Developments
- 12.11 Aurobindo Pharma
- 12.11.1 Aurobindo Pharma Company Information
- 12.11.2 Aurobindo Pharma Business Overview
- 12.11.3 Aurobindo Pharma Revenue in Therapeutic Nuclear Drug Business (2021-2026)
- 12.11.4 Aurobindo Pharma Therapeutic Nuclear Drug Product Portfolio
- 12.11.5 Aurobindo Pharma Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst